  Many Huntington disease ( HD) mutation carriers already have cognitive and psychiatric symptoms in the premanifest ( premotor) phase of the disease , but the molecular underpinnings of these symptoms are not well understood. Previous work has shown reduced availability of the cerebral type 1 cannabinoid receptor ( CB